Literature DB >> 15138855

[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma].

B Hundsdorfer1, H-F Zeilhofer, K P Bock, P Dettmar, M Schmitt, H-H Horch.   

Abstract

This article examines the prognostic importance of urinase type plasminogen activators (uPA) and of plasminogen activator inhibitors (PAI-1) in cases of primary oral squamous cell carcinoma. Tissue samples were taken from the core of the tumour in 58 such primary surgical patients. The levels of uPA and PAI-1 were determined using ELISA. Statistical significance was calculated using the chi2- and log-rank tests. The mean follow-up (n=58) was 23 months. In order to determine prognostic value, the time before relapse was used. The mean time before relapse was 19 months. A total of 28 (40%) patients relapsed (local n=13, lymph node n=3, local and lymph node n=1, lymph node and skin n=1, other locations n=5). Such patients had significantly raised uPA (P<0.012) and PAI-1 (P<0.014) levels in the primary tumour. A optimal cutoff value for uPA (4.58 ng/mg) and PAI-1 (106.3 ng/mg) was determined using the multiple log-rank test. There was no significant correlation for patients with low or high levels (i.e. lower or higher than the cutoff value, respectively) with the usual clinical parameters such as localisation, N-stage, T-stage, differentiation and residual tumor status. Older patients (>58 years) had significantly higher levels of uPA and PAI-1 (P<0.017 and P<0.02, respectively). The likelihood of relapse was significantly higher in patients with high levels (uPA P<0.009, PAI-1 P<0.008). If the patients were divided into three groups depending on uPA and PAI-1 levels (group 1: uPA and PAI-1 low, n=35; group 2: uPA or PAI-1 high, n=12; group 3: uPA and PAI-1 high, n=11), relapses were more common in group 3 than in groups 1 or 2 (P<0.023). Patients with only surgical therapy (n=29) and those with postoperative radiotherapy (n=29) were used to evaluate postoperative follow-up. Cutoff levels were calculated for both groups. In the surgical therapy group this was uPA=5.63 ng/mg and PAI-1=106.3 ng/ml and in the surgical therapy plus radiotherapy group uPA=4.13 ng/mg and PAI-1=97.02 ng/mg. Kaplan-Meier curves showed a marked tendency for patients with higher levels to relapse more often. This is significant for surgical patients for PAI-1 (P<0.01) and for radiotherapy patients for uPA (P<0.04)

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138855     DOI: 10.1007/s10006-003-0520-x

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  24 in total

1.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

2.  Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production.

Authors:  M I Sherman; S Strickland; E Reich
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

3.  Effect of urokinase on the proliferation of primary cultures of human prostatic cells.

Authors:  J C Kirchheimer; J Wojta; G Hienert; G Christ; M E Heger; H Pflüger; B R Binder
Journal:  Thromb Res       Date:  1987-11-01       Impact factor: 3.944

4.  Chromosomal locations of human tissue plasminogen activator and urokinase genes.

Authors:  B Rajput; S F Degen; E Reich; E K Waller; J Axelrod; R L Eddy; T B Shows
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

Review 5.  Plasminogen activator inhibitors--a review.

Authors:  E K Kruithof
Journal:  Enzyme       Date:  1988

6.  Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer.

Authors:  H Nekarda; J R Siewert; M Schmitt; K Ulm
Journal:  Lancet       Date:  1994-01-08       Impact factor: 79.321

7.  Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

Authors:  L A Liotta; R H Goldfarb; R Brundage; G P Siegal; V Terranova; S Garbisa
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

8.  Activation of human breast carcinoma collagenase through plasminogen activator.

Authors:  M Paranjpe; L Engel; N Young; L A Liotta
Journal:  Life Sci       Date:  1980-04-14       Impact factor: 5.037

9.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.

Authors:  H Pedersen; J Grøndahl-Hansen; D Francis; K Osterlind; H H Hansen; K Danø; N Brünner
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

10.  Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.

Authors:  R L O'Grady; L I Upfold; R W Stephens
Journal:  Int J Cancer       Date:  1981-10-15       Impact factor: 7.396

View more
  5 in total

1.  SERPINE1 expression discriminates site-specific metastasis in human melanoma.

Authors:  R Matthew Klein; Daniel Bernstein; Steven P Higgins; Craig E Higgins; Paul J Higgins
Journal:  Exp Dermatol       Date:  2012-07       Impact factor: 3.960

2.  PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.

Authors:  Jennifer Freytag; Cynthia E Wilkins-Port; Craig E Higgins; J Andrew Carlson; Agnes Noel; Jean-Michel Foidart; Stephen P Higgins; Rohan Samarakoon; Paul J Higgins
Journal:  J Oncol       Date:  2010-03-01       Impact factor: 4.375

3.  PAI-1: An Integrator of Cell Signaling and Migration.

Authors:  Ralf-Peter Czekay; Cynthia E Wilkins-Port; Stephen P Higgins; Jennifer Freytag; Jessica M Overstreet; R Matthew Klein; Craig E Higgins; Rohan Samarakoon; Paul J Higgins
Journal:  Int J Cell Biol       Date:  2011-08-03

4.  Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades.

Authors:  Cynthia E Wilkins-Port; Stephen P Higgins; Craig E Higgins; Issey Kobori-Hotchkiss; Paul J Higgins
Journal:  Biochem Res Int       Date:  2012-02-20

5.  PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.

Authors:  Cynthia E Wilkins-Port; Craig E Higgins; Jennifer Freytag; Stephen P Higgins; J Andrew Carlson; Paul J Higgins
Journal:  J Biomed Biotechnol       Date:  2007-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.